“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,”
Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature diagnosis, which can rapidly and comprehensively measure an individual’s vaccine response, promising to take much of the initial guesswork out of predicting effective vaccines.
Professor Stephen Albert Johnston and Joseph Barten Legutki, used a mouse model of influenza infection to determine how the immunosignature of a natural infection can be used to discriminate between a protective and non-protective vaccine. The study appears in the October 28 early online edition of the Proceedings of the National Academy of Sciences.
Johnston is driven by the quest to develop disruptive technology that could make health care more effective and affordable. Despite 17 percent of the U.S. GDP tied to health care costs and growing, the U.S. does not get as much value per dollar as other countries (spending the most per capita yet ranking last in efficiency). He believes innovative diagnostic technologies that could determine whether or not an individual would get sick before symptoms appear, as well as the early identification of microbial culprits of infections has high potential for transforming medicine.
“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,” said Johnston, who directs the Center for Innovations and Medicine at the Biodesign Institute “In this work we demonstrate that it may also be useful for screening candidate vaccines.”
Currently, the effectiveness of vaccines is evaluated by looking for the presence a particular type of antibody from the vaccine-generated immune response or by extensive and complicated sets of analyses. The power of the immunosignature is that this effectiveness can be completed in one fell swoop, by using thousands of random molecules aligned on a microscope slide, like the transistors on a computer chip.
“We use an array of 10,000 short peptides, each one about twenty amino acids long, to generate a high degree of specificity and sensitivity for measuring both human, dog, and mouse infections and chronic and genetic diseases,” said Legutki, a faculty in CIM and lead author of the paper. “A subset of these peptides will stand out, based on an individual’s antibody repertoire, and provide a unique pattern, or signature for a given disease.”
In the study, they used a mouse H1N1 flu model system. This included both seasonal forms of influenza or inactive control, as well as several commercially available vaccines that could provide full or partial protection, and asked whether or not the immunosignature could predict vaccine effectiveness. They also examined individual differences among those receiving the same vaccine, and whether the immunosignature profile could have the power to reveal what parts of influenza virus were doing the most harm.
They found that the live and inactive forms of the virus produced different immunosignatures, with different intensities of immune response, yet both contained a core immunosignature of the virus.
Go deeper with Bing News on:
Immunosignature diagnosis
- Diagnosis of Allergic Bronchopulmonary Aspergillosis: A Case-Based Approach
Herein, we utilize a case-based approach to elaborate on the diagnosis of this disease. The review intends to provide a lucid understanding of the diagnostic process for the expert as well as the ...
- King Charles's Cancer Diagnosis and Treatment Timeline
After sharing the news of the King's diagnosis, Buckingham Palace said they will not be sharing regular updates on his health or treatment. Here, a complete timeline of what the Palace and other ...
- Bacterial Vaginosis: An Update on Diagnosis and Treatment
Symptoms of vaginitis are overall, however, rather nonspecific and therefore clinical diagnosis will at best give an indication of the presence of vaginitis, and warrants microscopic investigation ...
- King Charles to Resume Public Duties After Cancer Diagnosis, Doctors Are ‘Very Encouraged by the Progress Made So Far’
King Charles is resuming public duties following his February cancer diagnosis. In a statement issued on Friday alongside a new photo of the King with his wife, Queen consort Camilla, Buckingham P ...
- King Charles to resume public duties after cancer diagnosis: palace
“His Majesty The King will shortly return to public-facing duties after a period of treatment and recuperation following his recent cancer diagnosis,” the palace said in a brief statemen ...
Go deeper with Google Headlines on:
Immunosignature diagnosis
[google_news title=”” keyword=”Immunosignature diagnosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vaccine development
- Launching an effective bird flu vaccine quickly could be tough, scientists warn
Federal health officials say the U.S. has the building blocks to make a vaccine to protect humans from bird flu, if needed. But experts warn we're nowhere near prepared for another pandemic.
- Biomaterial-based Vaccines Market Size & Trends
Biomaterial-based vaccines offer a platform for personalized vaccine development by enabling targeted delivery and enhanced immune responses, leading to more effective and tailored preventive ...
- Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55). The company reported sales of $167 million, ...
- MRNA vaccine effective in treating glioblastoma brain cancer in small trial
An experimental cancer vaccine can quickly reprogram a person's immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.
- Controlled human infection study paves the way to improving vaccines and therapeutics development
A first-of-its-kind study led by the University of Oxford has successfully investigated human immunity against COVID-19 in people who already have antibodies against it. The results suggest that ...
Go deeper with Google Headlines on:
Vaccine development
[google_news title=”” keyword=”vaccine development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]